Wave Life Sciences updates on WVE-006 regulatory plans

Accepted by SEC EDGAR 02/02/2026 - 07:41 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Wave Life Sciences Ltd. filed a current report noting it has issued a press release titled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The company highlights regulatory plans around its WVE-006 program for this genetic condition.

The press release is furnished as Exhibit 99.1 and incorporated by reference, while a cover page interactive data file is included as Exhibit 104. The report is signed by President and Chief Executive Officer Paul B. Bolno, M.D.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wave Life Sciences (WVE) disclose in this 8-K filing?

Wave Life Sciences disclosed that it issued a press release describing plans to accelerate regulatory engagement for WVE-006 for alpha-1 antitrypsin deficiency. The company attached this press release as Exhibit 99.1 and incorporated it by reference in the current report.

What is the focus of Wave Life Sciences’ WVE-006 program mentioned in the filing?

The WVE-006 program is focused on alpha-1 antitrypsin deficiency, as stated in the press release title referenced in the filing. The company emphasizes it now has full control of WVE-006 while planning to accelerate regulatory engagement around this therapeutic candidate.

How does Wave Life Sciences describe its plans for WVE-006 in this report?

Wave Life Sciences references a press release titled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” This wording indicates a focus on advancing interactions with regulators for the WVE-006 program.

Which exhibits are included with Wave Life Sciences’ 8-K about WVE-006?

The filing includes Exhibit 99.1, which is the press release describing plans for WVE-006 and regulatory engagement, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document. Both exhibits accompany the current report’s brief narrative.

Who signed Wave Life Sciences’ 8-K related to WVE-006 regulatory plans?

The 8-K is signed on behalf of Wave Life Sciences Ltd. by Paul B. Bolno, M.D., the company’s President and Chief Executive Officer. His signature confirms the company has duly caused the report to be filed under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001631574 0001631574 2026-02-02 2026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
7 Straits View #12-00, Marina One East Tower Singapore				018936
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 8.01 Other Events.

On February 2, 2026, Wave Life Sciences Ltd. issued a press release entitled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd. dated February 2, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Paul B. Bolno, M.D.
		Paul B. Bolno, M.D.
		President and Chief Executive Officer

Date: February 2, 2026